Proteograph™ XT Assay Kit
High-throughput and robust proteomics without compromising protein depth, accuracy, or precision.
Proteograph™ Product Suite
Push the boundaries of your proteomics studies with the Proteograph XT workflow
Venture deeper into the uncharted proteome more quickly and easily than ever.
Overview of Proteograph XT: High-fidelity proteomics
See how you can expand your view of the proteome to uncover novel proteins and variants with the unmatched Proteograph XT workflow in this 10-minute overview video.
Proteograph XT workflow
Seer’s workflow uncovers critical insights from the dynamic and complex proteome that other methods miss. With the Proteograph XT nanoparticle assay, researchers can detect rare protein variants and novel protein biomarkers in a seamless process that is accurate, precise, and reproducible for a wide variety of sample types and sizes.
Proteograph™ XT Assay Kit
SP100 Automation Instrument
Fully automated sample preparation, with minimal hands-on time and high reproducibility
Mass Spectrometry
Compatible with most LC-MS/MS instruments.
Proteograph™ Analysis Suite
Seamless data analysis for rapid biological insight into large-scale proteomics studies
The Proteograph Product Suite has four interconnected features that add dimension and capacity to discovery proteomics research
Unbiased, peptide-level, high-resolution fidelity
Gain high-resolution, direct sightlines into the proteome at the peptide level with our proprietary engineered nanoparticles that enrich for novel biomarkers and protein variants.
- Over 60,000 peptides and 8,000 proteins with next-generation LC-MS.
- High accuracy & reproducibility.
- Pennies per datapoint in total cost of discovery.
The Proteograph uncovers previously concealed novel biomarkers and identifies protein isoforms in non-small cell lung cancer study.
Donovan, Margaret KR, et al. — 2023 DOI: 10.1371/journal.pone.0282821
The Proteograph, coupled with mass spectrometry-based plasma proteome analysis, provides valuable insights into personalized human vaccine responses.
The first pQTL study using the Proteograph mass spectrometry-based proteomics workflow offers new insights for genetics-based drug discovery.
Automated with minimal hands-on time
Get to results faster with our automated workflow requiring minimal hands-on time. A single user can process hundreds of samples quickly and with confidence.
- 400 samples/week on a single SP100 instrument at 40 samples/run.
- Only 2 mass spec injections, and 1 hour to read out time per sample.
- Insights in minutes, not hours, using preconfigured data pipelines and software.
Multiple species and sample types
By identifying protein variants across diverse species, and across sample types, our Proteograph XT Assay adds flexibility and scope to your studies.
- Species agnostic for model organism research.
- Optimized for complex, high-dynamic range biofluids.
- Supplemental low volume protocol for limited sample input studies.
The Proteograph provides >3-fold increase in the number of Protein Groups IDs compared with a neat digestion.
Unique insight into Evotec’s study working with the Proteograph to access thousands of proteins undetectable by conventional proteomics techniques.
The Proteograph workflow surpasses the traditional direct digest method, offering comprehensive insights with limited sample volumes.
Large-scale studies for high-throughput labs
The scalability of the Proteograph Product Suite enables you to undertake large-scale studies of significance, with simplified data management, increasing important discovery power.
- Run 20k samples/year with 1 Proteograph Product Suite and 2 LC-MS.
- Automatic mass spectrometer data upload to analysis software.
- Cloud scalable information architecture.
Applications for the Proteograph XT
The Proteograph XT is engineered for versatility, capable of identifying protein variants across multiple species and sample types, including complex and low-volume samples like blood plasma or conditioned media. This makes its high-throughput workflow ideal for uncovering proteomics insights in a range of applications.
Application note
Host cell protein analysis
This application note describes how the Proteograph product suite can be successfully used for HCP analysis, delivering 4-6 times more identifications than other methods.
Application note
Model organisms
This application note demonstrates the Proteograph XT’s ability to enhance protein detection in model organisms without preprocessing, even for minimal sample volumes.
Application note
Conditioned media secretome samples
The Proteograph XT is capable of comprehensive proteomic characterization of conditioned media secretomes, without the need for traditional preprocessing and sample manipulation protocols.
Proteomics services and support
Seer offers a comprehensive suite of service options to meet diverse proteomics research needs.
- Service Providers: Offers targeted proteomics solutions from Seer.
- Global Partners: Collaborate with leading organizations to access Seer products and services worldwide.
- Seer Technology Access Center (STAC): Delivers white-glove services like rapid Proof of Principle analysis, and full end-to-end projects with key analytical insights.
- Proteograph Customer Portal: Useful resources from our team of experts that are always available to provide guidance and dedicated support.
See why leading experts choose Seer to advance their research
Working with Seer has transformed our multi-omics biomarker discovery initiatives. Seer’s Proteograph is allowing us to generate unbiased, quantitative data for over 3000 pig plasma proteins, enabling us to find new biomarker signatures of slow-progressing diseases like CLN3 Batten Diseases in animal models.
John Brudvig, Ph.D. Assistant Professor of Pediatrics and Rare Diseases Group
Sanford Research LinkedIn
We asked Seer, could we use their nanoparticles… and to our great relief and surprise and happiness… it worked really well! So, we have exactly what we wanted… [and] if it works with GLP-1, it's going to work for a lot of other biological molecules like it… for lots and lots of different small hormones that we need to measure accurately. All of this is maturing right now… to this really quite magical, remarkable time.
Jennifer Van Eyk, Ph.D. Professor of Medicine and Biomedical Engineering, Director, Precision Biomarker Laboratories
Cedar-Sinai Cancer Institute LinkedIn
We are very excited to leverage Seer technology to enable deep and fast plasma proteome analysis. The ability to profile thousands of proteins in a discovery manner within an hour from plasma is unprecedented. This capability has redefined how we think about leveraging mass spectrometry on myriad clinical and translational projects.
Josh Coon, Ph.D. Professor of Chemistry and Biomolecular Chemistry
University of Wisconsin–Madison LinkedIn
Having unbiased access to the proteome with peptide-level insights is necessary to truly understand the proteome, its variants and its connection to human health and disease. Myself and my colleagues at WCM-Q were very satisfied that the Seer Proteograph technology was able to provide this.
Karsten Suhre, Ph.D. Professor of Physiology and Biophysics & Director of the Bioinformatics Core
Weill Cornell Medicine - Qatar LinkedIn
The Seer Proteograph platform uniquely combines deep, discovery-mode proteomic profiling of plasma and serum with the ability to feasibly scale studies for analysis of large cohorts. The technology allows us to perform statistically powered proteomic biomarker discovery campaigns directly in clinically accessible, yet complex and historically challenging, liquid biopsy specimen types.
Mark R. Flory, Ph.D. Senior Scientist, Cancer Early Detection Advanced Research Center (CEDAR), Knight Cancer Institute
Oregon Health and Science University LinkedIn
The Proteograph enables us to generate large-scale unbiased proteomic data at unparalled speed and depth of coverage. Our multi-omics studies combine unbiased genomics, transcriptomics and metabolomics with extensive proteomics data from the Proteograph to provide an unprecedented systems biology view of every subject. This comprehensive biological data enables us to develop transformative products for early disease detection in cancer and other complex diseases.
Bruce Wilcox, Ph.D. VP of Proteomics
PrognomiQ LinkedIn
Contact us
Talk with our team of experts today to start expanding your lab’s capability for biological discovery.